About This Meeting:

Decades of research and chemical innovation around the gut hormones GLP-1 and GIP have revolutionized the treatment of diabetes and obesity, achieving results once possible only with surgery. Despite this success, our understanding of how these molecules work remains incomplete. Moreover, their broader potential in treating other diseases, such as neurodegenerative disorders, is just beginning to emerge. 

This Keystone Symposia conference on Incretin Biology and Therapeutics: Transforming Obesity and Associated Diseases will leverage the collective expertise of basic and clinical researchers teamed with pharmaceutical scientists to discuss cutting-edge insights into incretin biology and explore novel mechanisms and approaches necessary to further propel the treatment of obesity and numerous additional disease indications. Key themes include the latest mechanistic and methodological advances in incretin biology, constructive debate over GIP agonism versus antagonism, the consequences of lean mass loss and metabolic adaptation, and quantity versus quality of weight loss, along with novel biologies and targets beyond incretins, such as energy expenditure and alternative mechanisms of appetite control and gut-brain signaling. 

Joint programming with Adipose Tissue: From Cellular Mechanisms to Systemic Health will integrate incretin and adipose biology, offering a forum to rethink how hormonal, neural, immune, and tissue-specific mechanisms can be leveraged to achieve durable metabolic health. 

This conference positions itself as a unique forum to catalyze paradigm shifts in approaches to obesity management, with new therapeutic avenues made possible by chemical advances in small molecule agonist design, biased signaling, conjugated polyagonists, and extended drug exposure. It is expected to set a road map for the next generation of therapies that will provide transformative benefits across a spectrum of disease indications. 

Check out the speaker highlights in the video below: